StockNews.com Begins Coverage on Alimera Sciences (NASDAQ:ALIM)

StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research report sent to investors on Wednesday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other analysts have also weighed in on the stock. Alliance Global Partners reiterated a neutral rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. Maxim Group reaffirmed a hold rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. Finally, HC Wainwright cut shares of Alimera Sciences from a buy rating to a neutral rating and set a $6.00 price objective on the stock. in a research report on Tuesday, June 25th.

Alimera Sciences Stock Performance

Shares of ALIM opened at $5.59 on Wednesday. The company has a current ratio of 2.62, a quick ratio of 2.51 and a debt-to-equity ratio of 1.71. The firm’s fifty day simple moving average is $5.32 and its two-hundred day simple moving average is $4.16. Alimera Sciences has a 12 month low of $2.61 and a 12 month high of $5.65. The stock has a market capitalization of $292.85 million, a P/E ratio of -3.56 and a beta of 1.28.

Alimera Sciences (NASDAQ:ALIM) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The business had revenue of $27.00 million for the quarter, compared to the consensus estimate of $25.76 million. Alimera Sciences had a negative net margin of 23.74% and a negative return on equity of 53.49%. As a group, analysts predict that Alimera Sciences will post -0.13 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Glazer Capital LLC bought a new position in Alimera Sciences in the 2nd quarter valued at about $3,067,000. Gabelli Funds LLC purchased a new position in shares of Alimera Sciences during the second quarter valued at approximately $600,000. Renaissance Technologies LLC grew its holdings in Alimera Sciences by 3.9% during the second quarter. Renaissance Technologies LLC now owns 181,694 shares of the biopharmaceutical company’s stock worth $1,010,000 after buying an additional 6,900 shares in the last quarter. Rhumbline Advisers purchased a new stake in Alimera Sciences in the 2nd quarter valued at $113,000. Finally, Bank of New York Mellon Corp bought a new position in Alimera Sciences during the 2nd quarter valued at $344,000. Institutional investors and hedge funds own 99.83% of the company’s stock.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).